Thinking About Stopping Wegovy? What to Consider First

Why you are stopping matters as much as how

People consider stopping Wegovy for many different reasons: they have hit their goal weight, they are struggling with side effects, the cost has become a pressure, or life circumstances have changed. The reason matters because it shapes what your prescriber will recommend next.

If side effects are driving the decision, there are often alternatives to stopping completely. Persistent nausea, bloating, or stomach discomfort during dose increases, for example, can sometimes be managed by slowing the titration schedule rather than ending treatment altogether. The connection between stopping and stomach pain is worth understanding separately, because the two sometimes run in opposite directions to what people expect.

If you have reached a stable weight and feel ready to come off, that is a very different conversation with your prescriber than if you are stopping because of cost or supply. Either way, the question of when the right point to stop arrives is one the published evidence has started to address, and NICE's guidance on semaglutide recommends a maximum two-year course within a specialist service, with treatment reviewed if less than five per cent weight loss has occurred after six months on the maintenance dose. That review threshold is a useful practical prompt: if you are asking whether stopping is right, it is worth noting what your actual weight loss has been.

A quick check you can do right now: pull up the last three months of your weight records, whether that is a health app, a notebook, or photos of your scales. If the number has been flat for twelve weeks on maintenance dose, that is concrete information to bring to your prescriber rather than an impression.

What happens to your body when you stop

Semaglutide works by activating GLP-1 receptors involved in appetite regulation and the rate at which your stomach empties. Once your last injection clears your system, those effects fade. Appetite tends to return, often noticeably, within days to a couple of weeks. For many people this is a significant shift after months of feeling full on smaller portions.

The clinical profile of semaglutide shows that the weight-regulating effects are tied to the drug being present. The STEP 1 trial, published in the New England Journal of Medicine, demonstrated roughly 15% average body-weight reduction over 68 weeks; a subsequent extension study showed that participants who discontinued semaglutide regained the majority of that weight within a year. This is not a failure of willpower. It reflects the biology of the condition: obesity is a chronic disease, and the medicine was addressing it actively. Stopping removes that active component.

Some people also notice changes in digestion when they stop. Constipation or a change in bowel habits as gastric motility returns to its pre-treatment pace is not uncommon, and bloating during or after stopping is something many people experience. These symptoms are usually temporary.

Mood and energy levels can shift too, particularly if appetite returning leads to changes in eating patterns. This is worth monitoring, not alarming, and worth mentioning to your prescriber if it becomes significant.

Tapering versus stopping outright

Unlike some medicines, Wegovy does not have a universally mandated taper. The prescribing guidance does not specify that you must step down through each dose before stopping. In practice, though, many prescribers will suggest a gradual reduction from a high maintenance dose, particularly if you have been on 2.4mg for some time, because stepping down can soften both the appetite rebound and any gastrointestinal adjustment.

If you have only recently started treatment, perhaps on the 0.25mg starting dose, stopping is a simpler picture. The lower doses are primarily there to let your system adjust to the medicine, so there is little clinical complexity in stopping at that point, though you should still tell your prescriber.

Stopping abruptly from a high dose is unlikely to be dangerous, but the appetite return can feel sharper. A structured plan, agreed with your clinical team, gives you a clearer framework for the weeks that follow and makes the transition easier to manage practically.

Planning what comes next

This is the part of the decision that many people underplan. Stopping Wegovy without thinking about what replaces the appetite and weight regulation it provided leaves a gap. The question of maintaining weight after stopping is a genuine and practical one, and the evidence suggests that lifestyle changes taken seriously during treatment, protein intake, strength exercise, consistent sleep, give people the best footing to maintain progress afterwards.

For people considering a different licensed treatment rather than stopping altogether, an overview of the weight-management options available in the UK may be useful context. Mounjaro (tirzepatide), for instance, works through a dual receptor pathway and has a different clinical profile.

If you are stopping because of cost rather than because treatment has run its course, it is worth understanding exactly what is included in private prescriptions. The Wegovy pricing picture has changed considerably since Eli Lilly and Novo Nordisk adjusted their UK list prices, and different providers structure what is included differently. Prescription fees, delivery, aftercare support: these vary, and knowing the full cost of a service is different from knowing the per-pen price.

The NHS guidance on weight-management injections covers what to expect around stopping, including the diet and activity support that should accompany treatment and its end. It is worth a read, particularly the section on what happens when treatment finishes.

If you are at the point of making this decision and want to talk it through with a prescriber, start a free consultation with our clinical team at any stage of your treatment journey, including when you are thinking about stopping.